Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects.

Freudenreich O, McEvoy JP.

Clin Schizophr Relat Psychoses. 2012 Oct;6(3):115-21. Review.

PMID:
23006236
2.

EPS profiles: the atypical antipsychotics are not all the same.

Weiden PJ.

J Psychiatr Pract. 2007 Jan;13(1):13-24. Review.

PMID:
17242588
3.

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.

Volavka J, Citrome L.

Expert Opin Pharmacother. 2009 Aug;10(12):1917-28. doi: 10.1517/14656560903061309. Review.

PMID:
19558339
4.

[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].

Bret P, Bret MC, Queuille E.

Encephale. 2009 Apr;35(2):129-38. doi: 10.1016/j.encep.2008.03.007. Epub 2008 Jul 7. French.

PMID:
19393381
5.

First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Kelly DL, Conley RR, Carpenter WT.

Drugs. 2005;65(8):1113-38. Review.

PMID:
15907146
6.

A meta-analysis of the efficacy of second-generation antipsychotics.

Davis JM, Chen N, Glick ID.

Arch Gen Psychiatry. 2003 Jun;60(6):553-64.

PMID:
12796218
7.

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW.

Arch Gen Psychiatry. 2006 Oct;63(10):1079-87.

PMID:
17015810
8.

Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries.

Barbui C, Nosè M, Mazzi MA, Bindman J, Leese M, Schene A, Becker T, Angermeyer MC, Koeter M, Gray R, Tansella M.

Int Clin Psychopharmacol. 2006 Mar;21(2):73-9.

PMID:
16421457
9.

Conventional antipsychotic medications for schizophrenia.

Dixon LB, Lehman AF, Levine J.

Schizophr Bull. 1995;21(4):567-77. Review.

PMID:
8749885
10.

Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.

Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ; German Study Group on First-Episode Schizophrenia.

J Clin Psychiatry. 2007 Nov;68(11):1763-74.

PMID:
18052570
11.

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Epub 2010 Dec 3. Review.

PMID:
21129135
12.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
13.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

14.

Antipsychotics in the treatment of schizophrenia: an overview.

Tandon R.

J Clin Psychiatry. 2011;72 Suppl 1:4-8. doi: 10.4088/JCP.10075su1.01. Review.

15.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
16.

Strategies for dosing and switching antipsychotics for optimal clinical management.

Buckley PF, Correll CU.

J Clin Psychiatry. 2008;69 Suppl 1:4-17. Review.

17.

What do large scale studies of medication in schizophrenia add to our management strategies?

Agius M, Davis A, Gilhooley M, Chapman S, Zaman R.

Psychiatr Danub. 2010 Jun;22(2):323-8. Review.

18.

Pharmacological treatments for first-episode schizophrenia.

Robinson DG, Woerner MG, Delman HM, Kane JM.

Schizophr Bull. 2005 Jul;31(3):705-22. Epub 2005 Jul 8. Review.

PMID:
16006592
19.

Minimizing the non-extrapyramidal side-effects of antipsychotics.

Keks NA.

Acta Psychiatr Scand Suppl. 1996;389:18-24. Review.

PMID:
8985473
20.

Clinical experience in developing treatment regimens with the novel antipsychotic risperidone.

Kopala LC.

Int Clin Psychopharmacol. 1997 Sep;12 Suppl 4:S11-8. Review.

PMID:
9352341

Supplemental Content

Support Center